H
Hirotoshi Akita
Researcher at Hokkaido University
Publications - 32
Citations - 247
Hirotoshi Akita is an academic researcher from Hokkaido University. The author has contributed to research in topics: Lung cancer & Chemotherapy. The author has an hindex of 6, co-authored 30 publications receiving 194 citations.
Papers
More filters
Journal ArticleDOI
Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS study
Manfred Dietel,N. Savelov,R. Salanova,Patrick Micke,Gilbert Bigras,T. Hida,J. Antunez,B. Guldhammer Skov,G. Hutarew,L. F. Sua,Hirotoshi Akita,Oscar S.H. Chan,Bilal Piperdi,Thomas Burke,S. Khambata-Ford,A. C. Deitz +15 more
TL;DR: This is the largest real-world study in advanced NSCLC to date evaluating PD-L1 tumor expression using the 22C3 pharmDx kit and results were broadly consistent with central testing results from clinical trial screening populations.
Journal Article
Prognostic value of nuclear DNA content and expression of the ras oncogene product in lung cancer.
Hiroshi Miyamoto,Masao Harada,Hiroshi Isobe,Hirotoshi Akita,Hitoshi Haneda,Etsuro Yamaguchi,Noboru Kuzumaki,Yoshikazu Kawakami +7 more
TL;DR: It is suggested that DNA content or enhanced ras p21 expression may be different biological markers indicating the malignant potential of lung tumors, and DNA content was not a major independent prognostic factor in adenocarcinoma.
Journal ArticleDOI
A Phase III Comparison of Etoposide/Cisplatin with or without Added Ifosfamide in Small-Cell Lung Cancer
Hiroshi Miyamoto,Takeji Nakabayashi,Hiroshi Isobe,Hirotoshi Akita,Yoshikazu Kawakami,Takuro Arimoto,Mitsuo Asakawa,Akira Suzuki,Toshiaki Fujikane,Tetsuo Shimizu,Eiichi Sakai +10 more
TL;DR: The results suggest that PEI is not superior to PE chemotherapy in SCLC and the use of ifosfamide in multimodality treatment regimens needs to be studied further.
Journal ArticleDOI
Marked reduction of type I keratin (K14) in cisplatin-resistant human lung squamous-carcinoma cell lines.
Motoo Katabami,Hisaku Fujita,Kouichi Honke,Akira Makita,Hirotoshi Akita,Hiroshi Miyamoto,Yoshikazu Kawakami,Noboru Kuzumaki +7 more
TL;DR: This report is the first to suggest the possible association of marked K14 reduction and cisplatin resistance in PC 10-B3 and PC10-E5, from their original cell line PC10.
Journal Article
[Second-line treatment for advanced non-small-cell lung cancers].
TL;DR: Treatment with pemetrexed resulted in outcomes with clinically equivalent efficacy, but with significantly fewer side effects compared with docetaxel in two phase III trials, and should be considered a standard treatment option for second-line treatment when available.